Table of Contents

Locator Record

Title: Glycohemoglobin (L10_C )
Contact Number: 1-866-441-NCHS
Years of Content: 2003 - 2004
First Published: April, 2006
Revised: March, 2012
Access Constraints: None
Use Constraints: None
Geographic Coverage: National
Subject:Glycohemoglobin
Record Source: NHANES 2003 - 2004
Survey Methodology: NHANES 2003 - 2004 is a stratified multistage probability sample of the civilian non-institutionalized population of the U.S.
Medium: NHANES Web site; SAS transport files

Component Description

Diabetes mellitus will be assessed by measures of blood glycohemoglobin, plasma glucose, serum insulin, and serum c-peptide in participants aged 12 years and over.

Glycohemoglobin measures are available for a full sample. Measures of blood glycohemoglobin, plasma glucose, serum insulin, and serum c-peptide in the morning examination session only can be found in the Lab10AM data file.

Diabetes is a leading cause of disease and death in the United States. Eight million Americans are known to have diabetes, and an equal number have undiagnosed diabetes. In 1993, nearly 18 percent of all deaths for persons over the age of 25 were among people with diabetes. The prevalence of diabetes and overweight (one of the major risk factors for diabetes) continue to increase. Substantial new efforts to prevent or control diabetes have begun, including the Diabetes Prevention Trial and the National Diabetes Education Program.

Information on the prevalence of diabetes disease, especially in its early stages, and associated risk factors will be used to help develop early intervention and prevention programs for the disabling consequences of this condition. Specifically, the diabetes disease examination will provide population data to:

  1. determine a national estimate of diabetes disease prevalence (diagnosed and undiagnosed), including those at high risk for the late complications of the disease (i.e., ulceration and amputation);
  2. identify the risk factors of diabetes disease;
  3. permit a national cohort to be established for follow-up studies of this condition; and
  4. provide critical information to clinicians and public health officials for the development of preventive care and community-based interventions.

Eligible Sample

Participants aged 12 years and older were tested.

Description of Laboratory Methodology

Glycohemoglobin

Glycated proteins differ from non-glycated proteins by the attachment of a sugar moiety(s) at various binding sites by means of a ketoamine bond. Glycohemoglobin (GHb) thus contains 1,2-cis-diol groups not found in non-glycated proteins. These diol groups provide the basis for separation of glycated and non-glycated components by boronate affinity chromatography 11a,11b,11c. In this analytical technique, a boronate such as phenylboronic acid is bonded to the surface of the column support. When a solution of proteins (e.g. hemolysate) is passed through the column, the glycated component is retained by the complexing of its diol groups with the boronate. After the unretained non-glycated component elutes from the column, the glycated component is eluted from the column with a reagent that displaces it from the boronate.

The Primus instrument is a fully automated glycohemoglobin analyzer, which utilizes the principle of boronate affinity high performance liquid chromatography (HPLC)P 11dP. The analytical column contains aminophenylboronic acid bonded to a porous polymer support (gel). The low- and high-pressure pumps transfer reagents through the analytical column, with reagent selection executed by a switching valve. Hemolyzed samples are automatically injected onto the column during the flow of A-Elution Reagent #1. The glycated component binds to the boronate, while the non-glycated component passes through the column to the spectrophotometric detector, where it is detected at wavelength of 413-±2 nm. After the elution of non-glycated component, the Primus instrument pumps B-Elution Reagent #2, which displaces the glycated component from the column. The glycated component then passes through the detector. In the final stage of each sample cycle, the column is re-equilibrated with Elution A-Reagent #1. All reagent selection occurs in a timed sequence designed to allow complete elution of non-glycated and glycated components.

Microprocessors (Model CLC330) or the PC computer (Model CLC385) control all functions in the liquid chromatograph and computing integrator. The signal from the spectrophotometric detector is processed and the concentration of glycohemoglobin is calculated as a percentage of the total detected. Integration is by peak area in millivolt-seconds. The chromatogram is plotted first as the signal is received by the detector. The raw % glycohemoglobin is calculated when glycated hemoglobin peak area is divided by the total hemoglobin peak area. Primus HPLC uses two point calibrators with HbA1c assigned values to obtain a final standardized glycohemoglobin. The Schiff base does not interfere with boronate affinity method. The report is then printed with the sample information, raw Glycohemoglobin and standardized Glycohemoglobin results.

A detailed description of the laboratory method used can be found at NHANES web page.

 

Data Processing and Editing

Blood specimens were processed, stored and shipped to University of Missouri-Columbia, Columbia, Missouri for analysis. Detailed specimen collection and processing instructions are discussed in the NHANES Laboratory/Medical Technologists Procedures Manual (LPM). Read the LABDOC file for detailed data processing and editing protocols. The analytical methods are described in the Description of the Laboratory Methodology section.

There were no top coding or derived variables in this file.

Detailed instructions on specimen collection and processing can be found on the NHANES website.

Laboratory Quality Assurance and Monitoring

The NHANES quality control and quality assurance protocols (QA/QC) meet the 1988 Clinical Laboratory Improvement Act mandates. Detailed quality control and quality assurance instructions are discussed in the UNHANES Laboratory/Medical Technologists Procedures Manual (LPM)U. Read the LABDOC file for detailed QA/QC protocols.

There were no changes to the equipment, lab method, or lab site from the previous 2 years.

A detailed description of the quality assurance and quality control procedures can be found on the NHANES website.

Analytic Notes

Analytic note for analysis of Hemoglobin A1c (Glycohemoglobin) data for 1999-2010:

Removal of cross-over regression to compare Hemoglobin A1c data from 2005-2006 to 2003-2004:
The recommendation to use the Hemoglobin A1c (Glycohemoglobin) cross-over study regression equation to compare 2005-2006 (GHB_D) data to 2003-2004 (GHB_C) data has been withdrawn. Analyses of Hemoglobin A1c, including trend analysis, should use the original data without the use of the cross-over regression. A
correction to the documentation for 2005-2006 (GHB_D) removing this cross-over regression equation was posted on the NHANES web site in November 2011.

Re-Release of 2007-2010 Hemoglobin A1c data:

Hemoglobin A1c results for 2007-2008 (GHB_E) and 2009-2010 (GHB_F) were temporarily withdrawn in November 2011 to evaluate a shift to the right (increased values) in the distribution of Hemoglobin A1c in 2007-2010 compared to 1999-2006. After careful evaluation of participant data, laboratory quality control data and non-NHANES A1c studies, a cause for this shift in the distribution of Hemoglobin A1c could not be identified. Therefore, the Hemoglobin A1c data for 2007-2008 (GHB_E) and 2009-2010 (GHB_F) were re-released in March 2012 without changes to the data. The user will need to carefully consider the information presented in this analytic note when analyzing Hemoglobin A1c data from 1999-2010.

 Background:

Hemoglobin A1c (glycohemoglobin), a diabetes test that reflects plasma glucose for the previous 120 days, has been used to monitor diabetes for many years. In recent years, new clinical recommendations included applying hemoglobin A1c to the diagnoses of diabetes (6.5% or greater) and pre-diabetes (5.7%-6.4%) [Summary of revisions for the 2010 clinical practice recommendations. Diabetes Care 2010;33 Suppl 1:S3. PubMed PMID: 20042773; PubMed Central PMCID: PMC2797388].

In October 2011, an increase in the proportion of Hemoglobin A1c between 5.7-6.4% was noted in NHANES 2007-2010 compared to 1999-2006. Any minimal increase in Hemoglobin A1c would result in a notable increase in the proportion of Hemoglobin A1c between 5.7-6.4% since the lower cut-point (5.7%) is close to the middle of the Hemoglobin A1c distribution for NHANES participants. This increase in Hemoglobin A1c between 5.7-6.4% and the shift to the right (increased values) in the distribution of A1c for 2007-2010 led to a re-evaluation of the previously released NHANES A1c data. The evaluation of trends in NHANES A1c data included the assessment of laboratory instrument changes using cross-over studies, a review of participant Hemoglobin A1c data trends which occurred during NHANES 1999-2010, assessment of internal laboratory quality controls, and examination of external laboratory quality controls such as data from the National Glycohemoglobin Standardization Program (NGSP).

During 1999-2010, there were three Hemoglobin A1c laboratory instruments and two laboratories used in NHANES. Hemoglobin A1c was performed in the first laboratory on the Primus CLC330 (from 1999-2004) and then in the second laboratory on the Tosoh A1C 2.2 Plus (from 2005-2006). From 2007-2010, Hemoglobin A1c was performed in the second laboratory on the Tosoh A1C G7. Laboratory method cross-over studies were conducted at the time of each of the laboratory instrument changes. Both laboratories analyzing NHANES Hemoglobin A1c data from 1999-2010 were standardized by participating in the NGSP.

It was determined that the Hemoglobin A1c cross-over study regression equation to compare NHANES 2005-2006 data to 2003-2004 data resulted in an over-correction of the data and should not be used. The reason for withdrawing this cross-over regression was that the laboratories performing the Hemoglobin A1c were standardized (harmonized) using the NGSP and the laboratories demonstrated acceptable analytical performance using NGSP criteria for bias and imprecision. A correction to the documentation for 2005-2006 (GHB_D) was posted on the NHANES web site in November 2011. If this 2003-2006 cross-over study regression equation correction was used for A1c analyses, a review of any previous analyses should be performed without this cross-over regression equation to assess if there are any significant changes to the findings.

The distributional changes to Hemoglobin A1c between 1999-2006 and 2007-2010 persisted when the cross-over regression between 2003-2004 and 2005-2006 was not used. This change in A1c distributions resulted in higher estimates of the proportion of A1c greater than or equal to 5.7%. From 2005-2006 to 2007-2008, the age-adjusted weighted proportion of A1c between 5.7-6.4% in participants 18 years and older increased from 15.3 to 21.7%. Also, the proportion of A1c greater than or equal to 6.5% increased from 5.8 to 7.3% from 2005-2006 to 2007-2008.

The age-adjusted weighted Hemoglobin A1c (%) distribution for participants 18 years and older was the following:

Percentiles
Years n Mean 5th 25th 50th 75th 95th
1999-2000 4711 5.38 4.6 5 5.2 5.5 6.8
2001-2002 5297 5.47 4.8 5.1 5.3 5.5 6.7
2003-2004 5048 5.48 4.8 5.1 5.3 5.6 6.7
2005-2006 5022 5.44 4.6 5 5.3 5.6 6.6
2007-2008 5610 5.58 4.8 5.2 5.4 5.7 6.9
2009-2010 6029 5.62 4.8 5.2 5.5 5.8 6.9


 

On 11/04/2011, Hemoglobin A1c data for NHANES 2007-2008 (GHB_E) and 2009-2010 (GHB_F) were temporarily withdrawn from the public data release in order to further evaluate the possible reason for the increased Hemoglobin A1c.

Participant data for Hemoglobin A1c from 1999-2010 were then reviewed to determine if survey design changes were the reason for the increase of A1c in 2007-2010. Unweighted and weighted analyses of Hemoglobin A1c by specific age groups, gender, race/ethnic and body mass index (BMI) categories showed shifts to the right (increased values) between 1999-2006 compared with 2007-2010 in the Hemoglobin A1c distribution, and increases in the proportion of A1c between 5.7-6.4%. This change in the A1c distribution was seen in most subgroups which suggested a possible laboratory method etiology and not a survey design issue. The change in the A1c distribution from 2005-2006 to 2007-2008 included subgroups such as participants with normal BMI and younger participants, where increases in Hemoglobin A1c values would not be expected over a relatively short time. In addition, the participant trends in fasting plasma glucose (FPG) and 2-hour oral glucose tolerance test (OGTT) data were examined to see if they correlated with increased trends in Hemoglobin A1c. The NHANES FPG (2005-2010) and OGTT (2005-2010) were relatively stable and did not show the same magnitude of increase in 2007-2010 as Hemoglobin A1c, and would possibly suggest that the increase in Hemoglobin A1c was a laboratory method issue.

Internal and external laboratory quality controls were evaluated to determine if laboratory method changes were the reason for the increased Hemoglobin A1c. These included evaluation of the internal “bench” quality controls for imprecision. For 2007-2010, the internal quality control coefficients of variation ranged from 1.2-1.5% for Hemoglobin A1c concentration range of 5.3-5.4%. The laboratories performing NHANES Hemoglobin A1c from 1999-2010 participated in the NGSP, an external standardization program that certifies the laboratories for bias and precision for Hemoglobin A1c. The NGSP sends to each laboratory monthly a set of 10 whole blood specimens (Hemoglobin A1c range from 4-10%) and the specimens are analyzed in singlet for 2 days. The NSGP laboratories are compared to a central primary reference lab and to other similarly certified laboratories. The NGSP criteria for acceptable A1c bias is +/- 0.35% and the acceptable precision is not to exceed a standard deviation of 0.229, based on the difference of sample replicates. From 1999-2010, both NHANES laboratories did not exceed the NGSP Hemoglobin A1c criteria for bias or precision in any month. For 2007-2010, the NHANES laboratory had an average yearly A1c bias ranging from -0.10 to +0.02% from the NGSP central primary reference laboratory (yearly mean A1c ranged from 7.5 to 8.1% for the central primary reference laboratory). It would be expected that the NGSP bias would be more positive based on the increased Hemoglobin A1c seen in the NHANES participant data from 2007-2010. In addition, for 2005-2010, the NHANES laboratory’s bias compared well to other similarly certified NGSP (secondary reference) laboratories that used other types of Hemoglobin A1c methods. Another external comparison performed by the NHANES laboratory used in 2005-2010 was the analysis of specimens obtained biannually from the International Federation of Clinical Chemistry (IFCC). The IFCC laboratory is used to confirm the “master” equation that relates Hemoglobin A1c values in the United States to the rest of the world. The NHANES laboratory and the NGSP central reference laboratory correlated well to the IFCC A1c values. In conclusion, the NHANES laboratory used from 2005-2010 had acceptable analytical performance for bias and precision.

A laboratory group from the NGSP system was consulted by NCHS in February 2012 to review the NHANES laboratory and participant Hemoglobin A1c data. The NGSP group concluded that both NHANES laboratories met NGSP criteria for bias and precision from 1999-2010. In addition, the EDIC (Epidemiology of Diabetes Interventions and Complications) study, a longitudinal study of type 1 diabetic persons that had Hemoglobin A1c performed in the same NHANES laboratory during 2005-2010, was evaluated to see if similar increases in Hemoglobin A1c occurred. For the EDIC participants in the lower 10th percentile (similar Hemoglobin A1c values to NHANES), the A1c values were relatively stable, but the sample size was small (less than 200 participants). Other laboratory factors including pre-analytical issues (sample collection and anticoagulants) and commutablility (caused by differences in sample matrix between participants and laboratory controls) were considered but determined not likely to contribute to the increase in Hemoglobin A1c seen in 2007-2010. The NGSP laboratory group felt that the NGSP system currently had insufficient precision at the lower pre-diabetes cut-point of 5.7% to detect the Hemoglobin A1c changes seen in NHANES 2005-2010.

In conclusion, the increase in Hemoglobin A1c in 2007-2010 seen in NHANES participants by age, gender, race/ethnicity and BMI and not seen to the same magnitude in participant fasting plasma glucose and oral glucose tolerance test values suggested a possible laboratory method etiology. However, the laboratory’s internal quality control, external NGSP data, and Hemoglobin A1c data performed for non-NHANES studies during 2007-2010 suggested no laboratory method issues related to the shift to the right (increased values) of the Hemoglobin A1c distribution and the proportion of A1c between 5.7-6.4%. In summary, despite intensive studies to determine the etiology of the A1c trend increase, it was not possible to determine if laboratory method, survey design effect or population changes caused the increase in the Hemoglobin A1c. Therefore, after careful evaluation of participant data and data from the laboratory performing the Hemoglobin A1c, the Hemoglobin A1c data for 2007-2008 (GHB_E) and 2009-2010 (GHB_F) were re-released in March 2012 without changes to the data. The user will need to carefully consider the information presented in this analytic note when analyzing Hemoglobin A1c data from 1999-2010.

The analysis of NHANES 2003-2004 laboratory data must be conducted with the key survey design and basic demographic variables. The NHANES 2003-2004 Household Questionnaire Data Files contain demographic data, health indicators, and other related information collected during household interviews. They also contain all survey design variables and sample weights for these age groups. The phlebotomy file includes auxiliary information such as the conditions precluding venipuncture. The household questionnaire and phlebotomy files may be linked to the laboratory data file using the unique survey participant identifier SEQN.

LBXGH: Glycohemoglobin

Glycohemoglobin measurements for NHANES 2003-2004 were performed by the Diabetes Diagnostic Laboratory at the University of Missouri-Columbia using Primus CLC330 and Primus CLC 385 (Primus Corporation, Kansas City, MO). The Boronate Affinity High Performance Liquid Chromatography (HPLC) system determines total glycohemoglobin by measuring 1,2-cis diol group found in glycated hemoglobin. The system has been standardized to the reference method used for the Diabetes Control and Complications Trial (DCCT). The affinity chromatographic method has demonstrated excellent, long-term precision (interassay CV's <3.0%) and is not affected by the presence of hemoglobin variants S, C, D and elevated HbF. The method is also less sensitive to hemoglobin degradation due to improper sample handling.

References

Codebook and Frequencies

SEQN - Respondent sequence number

Variable Name:
SEQN
SAS Label:
Respondent sequence number
English Text:
Respondent sequence number.
Target:
Both males and females 12 YEARS - 150 YEARS

LBXGH - Glycohemoglobin (%)

Variable Name:
LBXGH
SAS Label:
Glycohemoglobin (%)
English Text:
Glycohemoglobin (%)
Target:
Both males and females 12 YEARS - 150 YEARS
Code or Value Value Description Count Cumulative Skip to Item
3.3 to 18 Range of Values 6601 6601
. Missing 389 6990